{"url_path":"/sec/zyme/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1937653/0001193125-26-224161-index.html","accession_number":"0001193125-26-224161","cik":"0001937653","ticker":"ZYME","issuer_name":"Zymeworks Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1937653/0001193125-26-224161-index.html","primary_entity_key":"0001937653","primary_entity_name":"Zymeworks Inc."},"word_count":152,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn May 14, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing that its Board of Directors (the “Board”) had authorized a share repurchase program (the “2026 Share Repurchase Program”) under which the Company may repurchase up to $125.0 million of the Company’s common stock, par value $0.00001 per share (the “Common Stock”). In connection with approval of the 2026 Share Repurchase Program, the Board terminated the previous authorization of up to $125.0 million of repurchases of Common Stock (the “2025 Repurchase Program”), under which an aggregate of 4,197,553 shares of Common Stock were repurchased with an average price of $24.36 per share, for total repurchases of $102.3 million (exclusive of commission expense and estimated excise tax).\n\nA copy of the press release announcing the 2026 Share Repurchase Program is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference."}